title: Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine.
abstract: Treatment of pediatric migraine remains an unmet medical need. There continues to be a paucity of pediatric randomized controlled trials for the treatment of migraine, both in the acute and preventive settings. Pediatric studies are often complicated by high placebo-response rates and much of our current practice is based on adult trials. This lack of significant pediatric studies results in a wide variation in migraine management both amongst clinicians and between institutions, and evidence-based treatments are not always administered. In this article, we aim to briefly review newly approved abortive and preventive agents for migraine in the pediatric age group. Over-the-counter anti-inflammatory medications, including ibuprofen, naproxen sodium, aspirin, and acetaminophen are reasonable first-line options for abortive therapy. In addition, studies have shown triptans, or migraine-specific agents, to be safe and effective in children and adolescents and several formulations have been approved for the pediatric population, including rizatriptan, almotriptan, zolmitriptan nasal spray, and naproxen sodium/sumatriptan in combination.
authors: Division of Neurology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH, 45229, USA. Joanne.Kacperski@cchmc.org.|College of Medicine, University of Cincinnati, Cincinnati, OH, USA. Joanne.Kacperski@cchmc.org.
authors: Joanne
authors: 0000-0003-0226-7668
authors: J
authors: Kacperski
authors: Division of Neurology, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, OH, 45229, USA.|College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
authors: Andrew D
authors: AD
authors: Hershey
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D017277:Drug Approval; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D004366:Nonprescription Drugs / Q000627:therapeutic use; D014363:Tryptamines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D004366:Nonprescription Drugs; D014363:Tryptamines